Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 11/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160180 | 0.95 | NOTUM (0.51) | ESRRANOTUMAMY1A | |
| SCHEMBL25494366 | 0.83 | CA12 (0.42) | NOTUMS1PR1 | |
| SCHEMBL13183607 | 0.81 | NOTUM (0.53) | ESRRANOTUM | |
| SCHEMBL13160236 | 0.80 | NOTUM (0.41) | ESRRANOTUM | |
| SCHEMBL9729936 | 0.79 | FLT3 (0.46) | ESRRANOTUM | |
| SCHEMBL13119830 | 0.79 | P2RX7 (0.50) | ESRRANOTUM | |
| SCHEMBL19589440 | 0.77 | MAOA (0.50) | ESRRANOTUM | |
| SCHEMBL13183643 | 0.77 | ESRRA (0.52) | ESRRANOTUMS1PR1AMY1A | |
| SCHEMBL20644410 | 0.77 | ESRRA (0.46) | ESRRANOTUMS1PR1 | |
| SCHEMBL20046658 | 0.77 | RXRA (0.41) | ESRRANOTUMS1PR1AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | ESRRA 3126/4885NOTUM 4812/4885S1PR1 1602/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | ESRRA 2865/4885NOTUM 4685/4885S1PR1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.